PK/PD Study of Intranasal Insulin in Type I Diabetes
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to compare the safety and tolerability of two different doses of
intranasally administered regular human insulin with those of a single dose of the
rapid-acting insulin analog lispro Humalog® after subcutaneous injection. In addition to
safety and tolerability, various pharmacokinetic (PK) and pharmacodynamic (PD) parameters
will be evaluated by means of the euglycemic glucose clamp technique.